Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint Medicines Gets CRL for Ayvakit in Fourth-Line Gist
04:16pm, Monday, 18'th May 2020
The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug -
09:21am, Monday, 18'th May 2020
One hit, one miss for GIST patients as FDA approves Deciphera’s Qinlock and rejects Blueprint Medicine’s Ayvakit as fourth-line therapy
U.S. FDA declines to approve Blueprint's therapy for type of stomach cancer
04:10pm, Friday, 15'th May 2020
Shares of the company fell 3.5% to $62.02 in premarket trading. The regulator in its so-called complete response letter said that Blueprint's application could not be approved in the current form. T
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug
Edited Transcript of BPMC earnings conference call or presentation 6-May-20 12:30pm GMT
03:29am, Friday, 15'th May 2020
Q1 2020 Blueprint Medicines Corp Earnings Call
Edited Transcript of BPMC earnings conference call or presentation 6-May-20 12:30pm GMT
10:05pm, Thursday, 14'th May 2020
Q1 2020 Blueprint Medicines Corp Earnings Call
All You Need to Know About Blueprint Medicines (BPMC) Rating Upgrade to Buy
04:00pm, Thursday, 14'th May 2020
Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated cli
How Blueprint Medicines (BPMC) Stock Stands Out in a Strong Industry
03:36pm, Tuesday, 12'th May 2020
Blueprint Medicines (BPMC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y
04:58pm, Thursday, 07'th May 2020
Blueprint Medicines (BPMC) betters loss estimates while revenues beat the mark in the first quarter. Higher collaboration revenues and a surge in product sales aid results.
Blueprint Medicines (BPMC) Q1 2020 Earnings Call Transcript
12:01pm, Thursday, 07'th May 2020
Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines conference call. This is Kristin Hodous of Blueprint Medicines, and welcome to Blueprint Medicines' first-quart
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
12:35pm, Wednesday, 06'th May 2020
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 1.86% and 27.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines Reports First Quarter 2020 Financial Results
11:00am, Wednesday, 06'th May 2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provide
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
